IgA antibody dynamics in healthcare workers after CoronaVac® vaccination and heterologous Comirnaty® booster dose.
Immunization
Immunoglobulin A
Pandemic
Public health
SARS-CoV-2
Vaccine
Journal
Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]
ISSN: 1678-4405
Titre abrégé: Braz J Microbiol
Pays: Brazil
ID NLM: 101095924
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
21
11
2022
accepted:
15
02
2023
medline:
5
6
2023
pubmed:
3
3
2023
entrez:
2
3
2023
Statut:
ppublish
Résumé
This study is aimed at calculating the IgA antibody dynamic range in healthcare workers (HCWs) after immunization with CoronaVac® and Comirnaty® booster dose. A total of 118 HCW serum samples from Southern Brazil were collected the day before the first vaccine dose (day 0) and + 20, + 40, + 110, + 200 days following the vaccine's first dose, and + 15 days after a Comirnaty® booster dose. Immunoglobulin A (IgA) was quantified using immunoassays for anti-S1 (spike) protein antibodies (Euroimmun, Lübeck, Germany). Seroconversion for the S1 protein occurred in 75 (63.56%) and 115 (97.47%) HCWs by day + 40 and day + 15 after the booster dose, respectively. There was an absence of IgA antibodies after the booster dose in two (1.69%) HCWs undergoing biannual rituximab administration and one (0.85%) HCW for no apparent reason. Complete vaccination showed a significant IgA antibody production response, and the booster dose considerably increased this response.
Sections du résumé
BACKGROUND
BACKGROUND
This study is aimed at calculating the IgA antibody dynamic range in healthcare workers (HCWs) after immunization with CoronaVac® and Comirnaty® booster dose.
METHODS
METHODS
A total of 118 HCW serum samples from Southern Brazil were collected the day before the first vaccine dose (day 0) and + 20, + 40, + 110, + 200 days following the vaccine's first dose, and + 15 days after a Comirnaty® booster dose. Immunoglobulin A (IgA) was quantified using immunoassays for anti-S1 (spike) protein antibodies (Euroimmun, Lübeck, Germany).
RESULTS
RESULTS
Seroconversion for the S1 protein occurred in 75 (63.56%) and 115 (97.47%) HCWs by day + 40 and day + 15 after the booster dose, respectively. There was an absence of IgA antibodies after the booster dose in two (1.69%) HCWs undergoing biannual rituximab administration and one (0.85%) HCW for no apparent reason.
CONCLUSION
CONCLUSIONS
Complete vaccination showed a significant IgA antibody production response, and the booster dose considerably increased this response.
Identifiants
pubmed: 36862369
doi: 10.1007/s42770-023-00935-1
pii: 10.1007/s42770-023-00935-1
pmc: PMC9978283
doi:
Substances chimiques
sinovac COVID-19 vaccine
0
BNT162 Vaccine
0
Immunoglobulin A
0
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
921-927Informations de copyright
© 2023. The Author(s) under exclusive licence to Sociedade Brasileira de Microbiologia.
Références
Infect Dis Rep. 2021 Oct 28;13(4):924-929
pubmed: 34842753
Vaccines (Basel). 2021 Sep 28;9(10):
pubmed: 34696200
Expert Rev Vaccines. 2021 Oct;20(10):1211-1220
pubmed: 34415818
JCI Insight. 2021 May 10;6(9):
pubmed: 33822773
Science. 2021 Jun 11;372(6547):1138
pubmed: 34112673
Lancet. 2021 Sep 4;398(10303):856-869
pubmed: 34370971
Eur J Intern Med. 2021 Jun;88:1-8
pubmed: 33966930
Lancet Infect Dis. 2021 Feb;21(2):181-192
pubmed: 33217362
N Engl J Med. 2021 Sep 9;385(11):1049-1051
pubmed: 34260850
Allergy. 2022 Aug;77(8):2381-2392
pubmed: 35124800
EBioMedicine. 2020 Dec;62:103101
pubmed: 33160207
Lancet. 2022 Feb 5;399(10324):521-529
pubmed: 35074136
Drugs. 2021 Mar;81(4):495-501
pubmed: 33683637
Physiol Res. 2020 Jul 16;69(3):379-388
pubmed: 32469225
Pathogens. 2022 Feb 24;11(3):
pubmed: 35335610
Clin Chim Acta. 2020 Aug;507:164-166
pubmed: 32343948
Lancet. 2021 Dec 4;398(10316):2093-2100
pubmed: 34756184
Am J Transplant. 2021 Dec;21(12):3990-4002
pubmed: 34453872
Nature. 2021 Dec;600(7890):701-706
pubmed: 34673755
Ann Rheum Dis. 2021 Oct;80(10):1361-1362
pubmed: 34167947
3 Biotech. 2021 Apr;11(4):198
pubmed: 33816047
N Engl J Med. 2022 Mar 17;386(11):1046-1057
pubmed: 35081293
Lancet Rheumatol. 2022 Jan;4(1):e13-e16
pubmed: 34778844
Sci Rep. 2020 Nov 30;10(1):20818
pubmed: 33257702
Diagn Microbiol Infect Dis. 2022 Mar;102(3):115597
pubmed: 34902621
Curr Opin Rheumatol. 2016 May;28(3):251-8
pubmed: 27027812